New access to Alzheimer's and other neurodegenerative diseases

Expert Review of Proteomics

Volumn 4, Issue 5, 2007, Pages 591-594

  Hamacher, Michael ^a   Meyer, Helmut E ^a   Marcus, Katrin ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; EDITORIAL; HEALTH CARE SYSTEM; METABOLIC REGULATION; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN DEGRADATION; QUALITY OF LIFE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANIMALS; HUMANS; MICE; MONOCYTES; NEURODEGENERATIVE DISEASES; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 35448965494     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.4.5.591     Document Type: Editorial

References (44)

1. Evans DA, Funkenstein HH, Albert MS et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 262, 2551-2556 (1989).
2. Hallauer J. Home nursing of demented patients as an economic factor in public health. Krankenpfl J. 42, 109-110 (2004).
3. Dodel RC, Hampel H, Du Y. Immunotherapy for Alzheimer's disease. Lancet Neurol. 2, 215-220 (2003).
4. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid-β peptide. Nat. Rev. Mol. Cell Biol. 8, 101-112 (2007).
5. Shen J, Kelleher RJ III. The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc. Natl Acad. Sci. USA 104, 403-409 (2007).
6. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc. Natl Acad. Sci. USA 103, 5644-5651 (2006).
7. Ding Q, Keller JN. Proteasomes and proteasome inhibition in the central nervous system. Free Radic. Biol. Med. 31, 574-584 (2001).
8. Ciechanover A, Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 40, 427-446 (2003).
9. Lindsten K, de Vrij FM, Verhoef LG et al. Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation. J. Cell Biol. 157, 417-427 (2002).
10. Butterfield DA. Amyloid β-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic. Res. 36, 1307-1313 (2002).
11. Canevari L, Abramov AY, Duchen MR. Toxicity of amyloid-β peptide: tales of calcium, mitochondria and oxidative stress. Neurochem. Res. 29, 637-650 (2004).
12. van Leeuwen FW, Hol EM, Fischer DF. Frameshift proteins in Alzheimer's disease and in other conformational disorders: time for the ubiquitin-proteasome system. J. Alzheimers Dis. 9, 319-325 (2006).
13. Song S, Kim SY, HongYM et al. Essential role of E2-25K/Hip-2 in mediating amyloid-β neurotoxicity. Mol. Cell 12, 553-563 (2003).
14. Luchsinger JA, Mayeux R. Adiposity and Alzheimer's disease. Curr. Alzheimer Res. 4, 127-134 (2007).
15. Luchsinger JA, Mayeux R. Cardiovascular risk factors and Alzheimer's disease. Curr. Atheroscler. Rep. 6, 261-266 (2004).
16. Peila R, Rodriguez BL, Launer LJ. Honolulu-Asia Aging Study. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51, 1256-1262 (2002).
17. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch. Neurol. 61, 661-666 (2002).
18. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285, 2486-2497 (2001).
19. Vanhanen M, Koivisto K, Moilanen L et al. Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology 67, 843-847 (2006).
20. Luchsinger JA, Mayeux R. Dietary factors and Alzheimer's disease. Lancet Neurol. 3, 579-587 (2004).
21. Scarmeas N, Stern Y, Mayeux R, Luchsinger JA. Mediterranean diet, Alzheimer disease, and vascular mediation. Arch. Neurol. 63, 1709-1717 (2006).
22. de la Monte SM, Tong M, Lester-Coll N, Plater M Jr, Wands JR. Therapeutic rescue of neurodegeneration in experimental Type 3 diabetes: relevance to Alzheimer's disease. J. Alzheimers Dis. 10, 89-109 (2006).
23. Farris W, Mansourian S, Chang Y et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo. Proc. Natl Acad. Sci. USA 100, 4162-4167 (2003).
24. Farris W, Mansourian S, Leissring MA et al. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid β-protein. Am. J. Pathol. 164, 1425-1434 (2004).
25. Grunblatt E, Salkovic-Petrisic M, Osmanovic J et al. Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats genrates hyperphosphorylated tau protein. J. Neurochem. 101, 757-770 (2007).
26. Rasgon N, Jarvik L. Insulin resistance, affective disorders, and Alzheimer's disease: review and hypothesis. J. Gerontol. A Biol. Sci. Med. Sci. 59, 178-183; discussion 184-192 (2004).
27. Whitmer RA. The epidemiology of adiposity and dementia. Curr. Alzheimer Res. 4, 117-122 (2007).
28. Strachan MW. Insulin and cognitive function. Lancet 362, 1253 (2003).
29. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 3, 169-178 (2004).
30. Reger MA, Watson GS, Frey WH II et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol. Aging 27, 451-458 (2007).
31. Cummings JL. Alzheimer's disease. N. Engl. J. Med. 351, 56-67 (2004).
32. Yamagishi S, Nakamura K, Inoue H, Kikuchi S, Takeuchi M. Possible participation of advanced glycation end products in the pathogenesis of colorectal cancer in diabetic patients. Med. Hypotheses 64, 1208-1210 (2005).
33. Yu YH, Ginsberg HN. Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circ. Res. 96, 1042-1002 (2005).
34. Ferrer I, Santpere G, Arzberger T et al. Brain protein preservation largely depends on the postmortem storage temperature: implications for study of proteins in human neurologic diseases and management of brain banks: a BrainNet Europe Study. J. Neuropathol. Exp. Neurol. 66, 35-46 (2007).
35. Streit WJ. Microglia and macrophages in the developing CNS. Neurotoxicology 22, 619-624 (2001).
36. Kaur C, Hao AJ, Wu CH, Ling EA. Origin of microglia. Microsc. Res. Tech. 54, 2-9 (2001).
37. Minagar A, Shapshak P, Fujimura R et al. The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J. Neurol. Sci. 202, 13-23 (2002).
38. Streit WJ. Microglia and Alzheimer's disease pathogenesis. J. Neurosci. Res. 77, 1-8 (2004).
39. Streit WJ, Conde JR, Fendrick SE et al. Role of microglia in the central nervous system's immune response. Neurol. Res. 27, 685-691 (2005).
40. Wahle T, Thal DR, Sastre M et al. GGA1 is expressed in the human brain and affects the generation of amyloid β-peptide. J. Neurosci. 26, 12838-12846 (2006).
41. Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J. Neuroimmunol. 184, 69-91 (2007).
42. Mrak RE, Griffin WS. Glia and their cytokines in progression of neurodegeneration. Neurobiol. Aging 26, 349-354 (2005).
43. Klegeris A, McGeer EG, McGeer PL. Therapeutic approaches to inflammation in neurodegenerative disease. Curr. Opin. Neurol. 20, 351-357 (2007).
44. Nagele RG, Wegiel J, Venkataraman V et al. Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease. Neurobiol. Aging 25, 663-674 (2004).